Cangrelor for the management and prevention of arterial thrombosis.

about

Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive 'real-world' patients.

P2860

Q38925026-EE3F8033-E749-48B1-A155-210AC7C96623

P2860

Cangrelor for the management and prevention of arterial thrombosis.

Item

http://www.wikidata.org/entity/Q38846758

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Cangrelor for the management and prevention of arterial thrombosis.

@en

type

Item

label

Cangrelor for the management and prevention of arterial thrombosis.

@en

prefLabel

Cangrelor for the management and prevention of arterial thrombosis.

@en

P1476

Cangrelor for the management and prevention of arterial thrombosis

@en

P2093

Akanksha Sinha

http://www.w3.org/2001/XMLSchema#string

P2860

Central role of the P2Y12 receptor in platelet activation

Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses

Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial

Bivalirudin during primary PCI in acute myocardial infarction

Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network.

Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.

Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.

P304

991-999

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14779072.2016.1207528

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Robert F. Storey

Akanksha Sinha

P577

2016-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27362653

http://www.w3.org/2001/XMLSchema#string

P921

thrombosis

Cangrelor for the management and prevention of arterial thrombosis.

about

P2860

P2860

Cangrelor for the management and prevention of arterial thrombosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921